{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T05:27:03Z","timestamp":1737523623882,"version":"3.33.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2007,11,2]],"date-time":"2007-11-02T00:00:00Z","timestamp":1193961600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharm Res"],"published-print":{"date-parts":[[2008,5]]},"DOI":"10.1007\/s11095-007-9473-3","type":"journal-article","created":{"date-parts":[[2007,11,2]],"date-time":"2007-11-02T15:32:31Z","timestamp":1194017551000},"page":"1125-1133","source":"Crossref","is-referenced-by-count":12,"title":["An Examination of the Effect of Intestinal First Pass Extraction on Intestinal Lymphatic Transport of Saquinavir in the Rat"],"prefix":"10.1007","volume":"25","author":[{"given":"Brendan T.","family":"Griffin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caitriona M.","family":"O\u2019Driscoll","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2007,11,2]]},"reference":[{"key":"9473_CR1","doi-asserted-by":"crossref","first-page":"461","DOI":"10.2165\/00003495-199855030-00014","volume":"55","author":"C. M. Perry","year":"1998","unstructured":"C. M. Perry and S. Noble. Saquinavir soft-gel capsule formulation. A review of its use in patients with HIV infection. Drugs 55:461\u2013486 (1998).","journal-title":"Drugs"},{"key":"9473_CR2","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1001\/jama.296.7.827","volume":"296","author":"S. M. Hammer","year":"2006","unstructured":"S. M. Hammer, M. S. Saag, M. Schechter, J. S. G. Montaner, R. T. Schooley, D. M. Jacobsen, M. A. Thompson, C. C. J. Carpenter, M. A. Fischl, B. G. Gazzard, J. M. Gatell, M. S. Hirsch, D. A. Katzenstein, D. D. Richman, S. Vella, P. G. Yeni, and P. A. Volberding. Treatment for adult HIV infection\u20142006 recommendations of the International AIDS Society\u2014USA panel. JAMA 296:827\u2013843 (2006).","journal-title":"JAMA"},{"key":"9473_CR3","first-page":"256","volume":"25","author":"M. E. Fitzsimmons","year":"1997","unstructured":"M. E. Fitzsimmons and J. M. Collins. Selective biotransformation of the human immunodeficiency virus protease inhibitor saquinavir by human small-intestinal cytochrome P4503A4: potential contribution to high first-pass metabolism. Drug Metab. Dispos. 25:256\u2013266 (1997).","journal-title":"Drug Metab. Dispos."},{"key":"9473_CR4","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/j.1365-2125.2004.02159.x","volume":"58","author":"M. Frohlich","year":"2004","unstructured":"M. Frohlich, M. M. Hoffmann, J. Burhenne, G. Mikus, J. Weiss, and W. E. Haefeli. Association of the CYP3A5 A6986G (CYP3A5*3) polymorphism with saquinavir pharmacokinetics. Br. J. Clin. Pharmacol. 58:443\u2013444 (2004).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"9473_CR5","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1023\/A:1011924314899","volume":"15","author":"J. Alsenz","year":"1998","unstructured":"J. Alsenz, H. Steffen, and R. Alex. Active apical secretory efflux of the HIV protease inhibitors saquinavir and ritonavir in Caco-2 cell monolayers. Pharm. Res. 15:423\u2013428 (1998).","journal-title":"Pharm. Res."},{"key":"9473_CR6","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/S0090-9556(24)15186-0","volume":"28","author":"C. B. Washington","year":"2000","unstructured":"C. B. Washington, H. R. Wiltshire, M. Man, T. Moy, S. R. Harris, E. Worth, P. Weigl, Z. Liang, D. Hall, L. Marriott, and T. F. Blaschke. The disposition of saquinavir in normal and P-glycoprotein deficient mice, rats, and in cultured cells. Drug Metab. Dispos. 28:1058\u20131062 (2000).","journal-title":"Drug Metab. Dispos."},{"key":"9473_CR7","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/mc.2940130302","volume":"13","author":"V. J. Wacher","year":"1995","unstructured":"V. J. Wacher, C. Y. Wu, and L. Z. Benet. Overlapping substrate specificities and tissue distribution of cytochrome-P450 3a and P-glycoprotein\u2014implications for drug-delivery and activity in cancer-chemotherapy. Mol. Carcinog. 13:129\u2013134 (1995).","journal-title":"Mol. Carcinog."},{"key":"9473_CR8","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0169-409X(97)00039-2","volume":"27","author":"K. E. Thummel","year":"1997","unstructured":"K. E. Thummel, K. L. Kunze, and D. D. Shen. Enzyme-catalyzed processes of first-pass hepatic and intestinal drug extraction. Adv. Drug Deliv. Rev. 27:99\u2013127 (1997).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"9473_CR9","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1124\/jpet.103.064394","volume":"310","author":"P. J. Sinko","year":"2004","unstructured":"P. J. Sinko, J. R. Kunta, H. H. Usansky, and B. A. Perry. Differentiation of gut and hepatic first pass metabolism and secretion of saquinavir in ported rabbits. J. Pharmacol. Exp. Ther. 310:359\u2013366 (2004).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"9473_CR10","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1124\/jpet.103.056390","volume":"308","author":"S. J. Mouly","year":"2004","unstructured":"S. J. Mouly, M. F. Paine, and P. B. Watkins. Contributions of CYP3A4, P-glycoprotein, and serum protein binding to the intestinal first-pass extraction of saquinavir. J. Pharmacol. Exp. Ther. 308:941\u2013948 (2004).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"9473_CR11","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1056\/NEJM199302043280508","volume":"328","author":"G. Pantaleo","year":"1993","unstructured":"G. Pantaleo, C. Graziosi, and A. S. Fauci. New concepts in the immunopathogenesis of human immunodeficiency virus infection. N. Engl. J. Med. 328:327\u2013335 (1993).","journal-title":"N. Engl. J. Med."},{"key":"9473_CR12","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1086\/319864","volume":"183","author":"H. F. Gunthard","year":"2001","unstructured":"H. F. Gunthard, D. V. Havlir, S. Fiscus, Z. Q. Zhang, J. Eron, J. Mellors, R. Gulick, S. D. Frost, A. J. Brown, W. Schleif, F. Valentine, L. Jonas, A. Meibohm, C. C. Ignacio, R. Isaacs, R. Gamagami, E. Emini, A. Haase, D. D. Richman, and J. K. Wong. Residual human immunodeficiency virus (HIV) Type 1 RNA and DNA in lymph nodes and HIV RNA in genital secretions and in cerebrospinal fluid after suppression of viremia for 2\u00a0years. J. Infect. Dis. 183:1318\u20131327 (2001).","journal-title":"J. Infect. Dis."},{"key":"9473_CR13","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1067\/mda.2002.124659","volume":"48","author":"O. J. Cohen","year":"2002","unstructured":"O. J. Cohen and A. S. Fauci. Current strategies in the treatment of HIV infection. DM Disease-a-Month 48:150\u2013184 (2002).","journal-title":"DM Disease-a-Month"},{"key":"9473_CR14","doi-asserted-by":"crossref","first-page":"8236","DOI":"10.1128\/JVI.00120-06","volume":"80","author":"M. Guadalupe","year":"2006","unstructured":"M. Guadalupe, S. Sankaran, M. D. George, E. Reay, D. Verhoeven, B. L. Shacklett, J. Flamm, J. Wegelin, T. Prindiville, and S. Dandekar. Viral suppression and immune restoration in the gastrointestinal mucosa of human immunodeficiency virus type 1-infected patients initiating therapy during primary or chronic infection. J. Virol. 80:8236\u20138247 (2006).","journal-title":"J. Virol."},{"key":"9473_CR15","first-page":"17","volume":"13","author":"C. O\u2019Driscoll","year":"2003","unstructured":"C. O\u2019Driscoll. Intestinal lymphatic targeting of drugs. STP Pharma Sciences 13:17\u201325 (2003).","journal-title":"STP Pharma Sciences"},{"key":"9473_CR16","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1211\/jpp.58.7.0006","volume":"58","author":"B. T. Griffin","year":"2006","unstructured":"B. T. Griffin and C. M. O\u2019Driscoll. A comparison of intestinal lymphatic transport and systemic bioavailability of saquinavir from three lipid-based formulations in the anaesthetised rat model. J. Pharm. Pharmacol. 58:917\u2013925 (2006).","journal-title":"J. Pharm. Pharmacol."},{"key":"9473_CR17","doi-asserted-by":"crossref","first-page":"A957","DOI":"10.1016\/S0016-5085(98)83900-0","volume":"114","author":"C. A. Cuvelier","year":"1998","unstructured":"C. A. Cuvelier, F. Berlioz, S. C. Dautrey, C. Roze, C. Carbon, and R. Farinotti. Intestinal absorption of saquinavir in the rat: insights in possible mechanisms. Gastroenterology 114:A957 (1998).","journal-title":"Gastroenterology"},{"key":"9473_CR18","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1146\/annurev.pharmtox.40.1.649","volume":"40","author":"C. Flexner","year":"2000","unstructured":"C. Flexner. Dual protease inhibitor therapy in HIV-infected patients: pharmacologic rationale and clinical benefits. Annu. Rev. Pharmacol. Toxicol. 40:649\u2013674 (2000).","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"9473_CR19","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1023\/A:1016217505990","volume":"12","author":"H. Saitoh","year":"1995","unstructured":"H. Saitoh and B. J. Aungst. Possible involvement of multiple P-glycoprotein-mediated efflux systems in the transport of verapamil and other organic cations across rat intestine. Pharm. Res. 12:1304\u20131310 (1995).","journal-title":"Pharm. Res."},{"key":"9473_CR20","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1096\/fasebj.6.2.1371482","volume":"6","author":"M. Maurice","year":"1992","unstructured":"M. Maurice, L. Pichard, M. Daujat, I. Fabre, H. Joyeux, J. Domergue, and P. Maurel. Effects of imidazole derivatives on cytochromes P450 from human hepatocytes in primary culture. FASEB J. 6:752\u2013758 (1992).","journal-title":"FASEB J."},{"key":"9473_CR21","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1023\/A:1007550717526","volume":"17","author":"M. A. Gibbs","year":"2000","unstructured":"M. A. Gibbs, M. T. Baillie, D. D. Shen, K. L. Kunze, and K. E. Thummel. Persistent inhibition of CYP3A4 by ketoconazole in modified Caco-2 cells. Pharm. Res. 17:299\u2013305 (2000).","journal-title":"Pharm. Res."},{"key":"9473_CR22","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/S0022-5347(17)34999-6","volume":"151","author":"M. J. Siegsmund","year":"1994","unstructured":"M. J. Siegsmund, C. Cardarelli, I. Aksentijevich, Y. Sugimoto, I. Pastan, and M. M. Gottesman. Ketoconazole effectively reverses multidrug resistance in highly resistant KB cells. J. Urol. 151:485\u2013491 (1994).","journal-title":"J. Urol."},{"key":"9473_CR23","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1023\/A:1018877803319","volume":"16","author":"R. B. Kim","year":"1999","unstructured":"R. B. Kim, C. Wandel, B. Leake, M. Cvetkovic, M. F. Fromm, P. J. Dempsey, M. M. Roden, F. Belas, A. K. Chaudhary, D. M. Roden, A. J. Wood, and G. R. Wilkinson. Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm. Res. 16:408\u2013414 (1999).","journal-title":"Pharm. Res."},{"key":"9473_CR24","first-page":"1452","volume":"49","author":"M. Naito","year":"1989","unstructured":"M. Naito and T. Tsuruo. Competitive inhibition by verapamil of ATP-dependent high affinity vincristine binding to the plasma membrane of multidrug-resistant K562 cells without calcium ion involvement. Cancer Res. 49:1452\u20131455 (1989).","journal-title":"Cancer Res."},{"key":"9473_CR25","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1080\/004982599238777","volume":"29","author":"R. D. Whalen","year":"1999","unstructured":"R. D. Whalen, P. N. V. Tata, G. J. Burckart, and R. Venkataramanan. Species differences in the hepatic and intestinal metabolism of cyclosporine. Xenobiotica 29:3\u20139 (1999).","journal-title":"Xenobiotica"},{"key":"9473_CR26","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1159\/000028214","volume":"56","author":"L. Salphati","year":"1998","unstructured":"L. Salphati and L. Z. Benet. Effects of ketoconazole on digoxin absorption and disposition in rat. Pharmacology 56:308\u2013313 (1998).","journal-title":"Pharmacology"},{"key":"9473_CR27","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1046\/j.1365-2125.1999.00999.x","volume":"48","author":"R. Sandstr\u00f6m","year":"1999","unstructured":"R. Sandstr\u00f6m, T. W. Knutson, L. Knutson, B. Jansson, and H. Lennern\u00e4s. The effect of ketoconazole on the jejunal permeability and CYP3A metabolism of (R\/S)-verapamil in humans. Br. J. Clin. Pharmacol. 48:180\u2013189 (1999).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"9473_CR28","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0378-5173(91)90042-M","volume":"73","author":"C. M. O\u2019Driscoll","year":"1991","unstructured":"C. M. O\u2019 Driscoll, R. A. Myers, and V. J. Stella. Blood and lymph transport of DDT after oral and parenteral administration to anaesthetized rats. Int. J. Pharm. 73:177\u2013183 (1991).","journal-title":"Int. J. Pharm."},{"key":"9473_CR29","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1002\/jps.2600541119","volume":"54","author":"W. E. Hamlin","year":"1965","unstructured":"W. E. Hamlin, J. I. Northam, and J. G. Wagner. Relationship between in vitro dissolution rates and solubilities of numerous compounds representative of various chemical species. J. Pharm. Sci. 54:1651\u20131653 (1965).","journal-title":"J. Pharm. Sci."},{"key":"9473_CR30","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1211\/jpp.58.6.0011","volume":"58","author":"L. Sek","year":"2006","unstructured":"L. Sek, B. J. Boyd, W. N. Charman, and C. J. H. Porter. Examination of the impact of a range of pluronic surfactants on the in-vitro solubilisation behaviour and oral bioavailability of lipiclic formulations of atovaquone. J. Pharm. Pharmacol. 58:809\u2013820 (2006).","journal-title":"J. Pharm. Pharmacol."},{"key":"9473_CR31","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1007\/s11095-006-9194-z","volume":"24","author":"J. F. Cuine","year":"2007","unstructured":"J. F. Cuine, W. N. Charman, C. W. Pouton, G. A. Edwards, and C. J. H. Porter. Increasing the proportional content of surfactant (Cremophor EL) relative to lipid in self-emulsifying lipid-based formulations of danazol reduces oral bioavailability in beagle dogs. Pharm. Res. 24:748\u2013757 (2007).","journal-title":"Pharm. Res."},{"key":"9473_CR32","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/0378-5173(86)90027-X","volume":"34","author":"W. N. A. Charman","year":"1986","unstructured":"W. N. A. Charman, and V. J. Stella. Estimating the maximal potential for intestinal lymphatic transport of lipophilic drug molecules. Int. J. Pharm. 34:175\u2013178 (1986).","journal-title":"Int. J. Pharm."},{"key":"9473_CR33","doi-asserted-by":"crossref","unstructured":"M. Achira, H. Suzuki, K. Ito, and Y. Sugiyama. Comparative studies to determine the selective inhibitors for P-glycoprotein and cytochrome P450 3A4. AAPS PharmSci 1 (1999).","DOI":"10.1208\/ps010418"},{"key":"9473_CR34","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1023\/A:1024422625596","volume":"20","author":"F. Seeballuck","year":"2003","unstructured":"F. Seeballuck, M. B. Ashford, and C. M. O\u2019Driscoll. The effects of Pluronic (R) block copolymers and Cremophor (R) EL on intestinal lipoprotein processing and the potential link with P-glycoprotein in Caco-2 cells. Pharm. Res. 20:1085\u20131092 (2003).","journal-title":"Pharm. Res."},{"key":"9473_CR35","doi-asserted-by":"crossref","first-page":"914","DOI":"10.7326\/0003-4819-129-11_Part_1-199812010-00022","volume":"129","author":"K. Brinkman","year":"1998","unstructured":"K. Brinkman, F. Huysmans, and D. M. Burger. Pharmacokinetic interaction between saquinavir and cyclosporine. Ann. Intern. Med. 129:914\u2013915 (1998).","journal-title":"Ann. Intern. Med."},{"key":"9473_CR36","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2165\/00003495-199652010-00007","volume":"52","author":"S. Noble","year":"1996","unstructured":"S. Noble and D. Faulds. Saquinavir\u2014A review of its pharmacology and clinical potential in the management of HIV infection. Drugs 52:93\u2013112 (1996).","journal-title":"Drugs"},{"key":"9473_CR37","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/S0928-0987(02)00051-9","volume":"15","author":"C. M. O\u2019Driscoll","year":"2002","unstructured":"C. M. O\u2019Driscoll. Lipid-based formulations for intestinal lymphatic delivery. Eur. J. Pharm. Sci. 15:405\u2013415 (2002).","journal-title":"Eur. J. Pharm. Sci."},{"key":"9473_CR38","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1124\/jpet.105.094094","volume":"316","author":"N. L. Trevaskis","year":"2006","unstructured":"N. L. Trevaskis, C. J. H. Porter, and W. N. Charman. The lymph lipid precursor pool is a key determinant of intestinal lymphatic drug transport. J. Pharmacol. Exp. Ther. 316:881\u2013891 (2006).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"9473_CR39","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1021\/js980185w","volume":"87","author":"S. M. Khoo","year":"1998","unstructured":"S. M. Khoo, J. H. Porter, G. A. Edwards, and W. N. Charman. Metabolism of halofantrine to its equipotent metabolite, desbutylhalofantrine, is decreased when orally administered with ketoconazole. J. Pharm. Sci. 87:1538\u20131541 (1998).","journal-title":"J. Pharm. Sci."},{"key":"9473_CR40","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1002\/1520-6017(200008)89:8<967::AID-JPS1>3.0.CO;2-R","volume":"89","author":"W. N. Charman","year":"2000","unstructured":"W. N. Charman. Lipids, lipophilic drugs, and oral drug delivery\u2014Some emerging concepts. J. Pharm. Sci. 89:967\u2013978 (2000).","journal-title":"J. Pharm. Sci."}],"container-title":["Pharmaceutical Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-007-9473-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11095-007-9473-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-007-9473-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T02:12:22Z","timestamp":1737511942000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11095-007-9473-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,11,2]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2008,5]]}},"alternative-id":["9473"],"URL":"https:\/\/doi.org\/10.1007\/s11095-007-9473-3","relation":{},"ISSN":["0724-8741","1573-904X"],"issn-type":[{"type":"print","value":"0724-8741"},{"type":"electronic","value":"1573-904X"}],"subject":[],"published":{"date-parts":[[2007,11,2]]}}}